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T cells genetically modified to enforce expression of a
chimeric antigen receptor (CAR) have shown consider-
able promise in clinical trials even in tumors refractory
to all other treatment methods. In particular, the use of
CAR T cells rendered specific for CD19 demonstrated
significant anti-tumor effects in patients with CD19+
chronic lymphocytic leukemia (CLL) and acute lympho-
blastic leukemia (ALL). Despite the clinical promise of
CAR therapy in achieving complete responses, their effi-
cacy remains unpredictable and new approaches are
needed to address this question and a priori define the
therapeutic potential of T cell based therapies. An inte-
gration of the existing clinical data suggests that the effi-
cacy of ACT is likely balanced by two requirements of
the T cell infusion product: immediate cytotoxicity to
enable eradication of the tumor and the ability to persist
and establish memory to ensure long term benefit.
Using our novel single cell multiparametric assay,
Timelapse Imaging Microscopy In Nanowell Grids
(TIMING), we compared the efficacy of two second
generation (CD28 endodomain) CD19 specific CAR
constructs, bearing CD8a and IgG4 hinge respectively,
by tracking their interaction with NALM6 tumor cells
in vitro. Although there were no discernible differences
using a population level assay, we demonstrate using
TIMING that significantly more CAR T cells bearing
the CD8a hinge participate in serial killing. This super-
ior efficacy was confirmed in a mouse model in which
CART cells containing the CD8a extracellular domain
were superior in controlling the disease.
In order to identify biomarkers which distinguish
between killer (and serial killer) CAR T cells and non-
killers, we performed single cell multiplexed gene
expression profiling (96 genes) subsequent to a TIMING
assay. Across three separate donors, killer CAR T cells
consistently expressed higher transcript levels of the
cytotoxic molecule Granzyme B, the costimulatory
receptor CD137 (41BB) and the regulatory receptor
TIM3 (HAVCR2).
By utilizing multicolor flow cytometry, we confirmed
that CD137 was overexpressed in cytotoxic CAR T cells
and that its stimulation was associated with higher cyto-
toxicity and lower expression level of the immunoregu-
latory receptors CTLA4 and PD1. By comparison, TIM3
was not enriched in killer CAR T cells but rather was a
likely marker for effector status since blocking TIM3
boosted cytotoxic responses.
In aggregate, these results demonstrate the utility of
our TIMING single cell methodology in uncovering not
only the dynamic profile of T cell behavior but in also
uncovering the phenotypic biomarkers of CAR T cells
with superior functional efficacy.
Authors’ details
1University of Houston, Houston, TX, USA. 2University of Texas MD Anderson
Cancer Center, Houston, TX, USA. 3University of Houston, University of the
Philippines, Houston, TX, USA.
Published: 4 November 2015
doi:10.1186/2051-1426-3-S2-P324
Cite this article as: Romain et al.: Single cell metrics of the efficacy of
CAR T cells. Journal for ImmunoTherapy of Cancer 2015 3(Suppl 2):P324.
1University of Houston, Houston, TX, USA
Full list of author information is available at the end of the article
Romain et al. Journal for ImmunoTherapy of Cancer 2015, 3(Suppl 2):P324
http://www.immunotherapyofcancer.org/content/3/S2/P324
© 2015 Romain et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
